J&J Q1 Earnings Beat: Growth Fueled by Key Pharma Products
Johnson & Johnson reported strong first-quarter financial results for 2026, with revenue reaching $24.06 billion and adjusted EPS of $2.70, both beating market expectations. The growth was significantly driven by key pharmaceutical products, including Darzalex, which saw a 22.5% sales increase, and Tremfya, which jumped 68%. Furthermore, the launch of the oral psoriasis pill, Icotyde, was highlighted as a major growth catalyst. While the revenue for the drug Stelara declined sharply due to patent expiration and biosimilar competition, analysts view this as a positive sign, indicating the company's successful transition to its high-growth pipeline. J&J also raised its full-year guidance, maintaining confidence in its diversified portfolio across pharmaceuticals and MedTech.
Ad slot
Johnson & Johnson reported strong first-quarter results for 2026, exceeding market expectations and signaling robust growth driven by its specialized pharmaceutical pipeline.
Q1 Financial Performance
J&J announced that its first-quarter revenue reached $24.06 billion, marking a 9.9% increase year-over-year and surpassing the LSEG consensus estimate of $23.63 billion. Adjusted earnings per share (EPS) for the quarter totaled $2.70, which was higher than the expected $2.66. The company also raised its full-year guidance across several key metrics.
Key Growth Drivers in Pharmaceuticals
The strong performance was primarily attributed to several high-growth medicines and pipeline launches:
Darzalex: Sales increased by 22.5% year-over-year, reaching $3.96 billion in the quarter. This growth is supported by the drug's use in earlier lines of treatment and improved administration methods.
Tremfya: Sales jumped 68% to $1.61 billion, benefiting from expanded approvals for inflammatory bowel disease (IBD).
Icotyde: The launch of this new oral pill for psoriasis was a major highlight. CEO Joaquin Duato noted its potential to become one of the company's largest products, especially when combined with Tremfya.
Ad slot
MedTech and Market Challenges
In the MedTech segment, total revenue reached $8.64 billion, slightly exceeding consensus. The segment's focus includes the Ottava robotic surgery system, which J&J is advancing to compete in a market dominated by other players.
However, the report highlighted a significant challenge in the pharmaceutical division:
Stelara: Revenue for the best-selling drug saw a sharp decline, falling almost 60% year-over-year. This drop is attributed to the loss of patent protection and increased competition from cheaper biosimilars.
Outlook and Investor Sentiment
Despite the decline in Stelara, analysts view the results positively, suggesting that the company is successfully navigating the patent cliff. The focus is shifting to the faster-growing pipeline products. J&J executives reaffirmed their commitment to achieving double-digit revenue growth by the end of the decade. The company plans to hold a business review meeting on December 8 to provide further details on its growth targets.
